title: Integrin β3 links therapy resistance and cancer stem cell properties.
abstract: Heterogeneity in tumour cell properties underlies many treatment failures. Understanding the sources of such heterogeneity has proved to be challenging, but remains critical to improving patient outcomes. Integrin α(v)β₃ expression in multiple types of solid tumour stem cells is now shown to control a pro-survival pathway that contributes to therapy resistance.
authors.forename: Nagarajan
authors.initials: N
authors.lastname: Kannan
authors.forename: Long V
authors.initials: LV
authors.lastname: Nguyen
authors.forename: Connie J
authors.initials: CJ
authors.lastname: Eaves
mesh_terms: D000818:Animals; D019008:Drug Resistance, Neoplasm; D066246:ErbB Receptors / Q000037:antagonists & inhibitors*; D005260:Female; D006801:Humans; D039661:Integrin beta3 / Q000378:metabolism*; D008175:Lung Neoplasms / Q000188:drug therapy*; D014411:Neoplastic Stem Cells / Q000187:drug effects*; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011518:Proto-Oncogene Proteins / Q000378:metabolism*; D016283:Proto-Oncogene Proteins p21(ras); D020725:ral GTP-Binding Proteins / Q000378:metabolism*; D018631:ras Proteins / Q000378:metabolism*
chemical_list: C061248:ITGB3 protein, human; D039661:Integrin beta3; C117307:KRAS protein, human; D047428:Protein Kinase Inhibitors; D011518:Proto-Oncogene Proteins; C483163:Ralb protein, human; C512478:EGFR protein, human; D066246:ErbB Receptors; D016283:Proto-Oncogene Proteins p21(ras); D020725:ral GTP-Binding Proteins; D018631:ras Proteins